Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Same author

SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma.

The Journal of experimental medicine·2024

Same author

<i>Erratum</i> to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.

Haematologica·2024

Same author

Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models.

Frontiers in immunology·2023

Same author

A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials.

EJHaem·2023

Same author

Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing.

Nature communications·2023

Search research articles

Related Experiment Video

Updated: May 17, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

Antibody-drug conjugate technology development for hematologic disorders.

Neil H Bander¹, Myron S Czuczman, Anas Younes

¹Weill Medical College/Cornell University, New York-Presbyterian Hospital and Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

Clinical Advances in Hematology & Oncology : H&O

|October 18, 2012

Summary

Antibody-drug conjugates (ADCs) represent an advancement in cancer therapy, combining targeted antibodies with potent chemotherapy. Modern ADCs feature improved linkers and highly effective drugs, leading to better efficacy and reduced side effects.

More Related Videos

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

Related Experiment Videos

Last Updated: May 17, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

Area of Science:

Oncology
Pharmacology
Biotechnology

Background:

Antibody-drug conjugates (ADCs) integrate antibody specificity with cytotoxic chemotherapy.
ADCs comprise a target antigen, antibody, linker, and cytotoxic drug.
The antibody guides the cytotoxic agent to tumor cells, minimizing side effects and enabling potent therapies.

Purpose of the Study:

To review the advancements in Antibody-drug conjugate (ADC) technology.
To highlight the evolution of linker stability and cytotoxic agent potency in ADCs.
To discuss the application and clinical trial status of ADCs in hematologic disorders.

Main Methods:

Review of ADC technology components and historical development.
Analysis of linker stability and cytotoxic agent potency improvements.
Examination of ADC applications against specific antigens (CD19, CD22, CD30) and clinical trial data.

Main Results:

Early ADCs suffered from labile linkers causing off-target toxicity.
Current ADCs utilize stable linkers and highly potent cytotoxic agents.
Approved ADC brentuximab vedotin shows efficacy in Hodgkin lymphoma and anaplastic large cell lymphoma.

Conclusions:

ADC technology has significantly improved, offering enhanced safety and efficacy.
Advancements in linker and drug components are key to modern ADC success.
Several ADCs are in clinical trials for hematologic malignancies, indicating a promising therapeutic area.